Standard Hybridoma Development Program
Abeome's DiSH technology is faster than conventional technologies and has been shown to produce more positive, stable hybridoma clones. The process includes:
Preparation of antigen
Client provides approximately 1.5 mg of antigen required for the project. (Abeome can also provide selected antigen preparation services.)
Immunizations and boosting
Abeome will immunize three mice per antigen. Test bleeds (by ELISA) are done on each animal prior to project initiation; results are made available. Immunization will be done using adjuvant(s). Boosts are given at approximately 28-day intervals. Client is shown all test bleed results and asked to decide whether to boost or harvest.
Harvest and fusion
Spleens will be harvested, processed, and fused with Abeome's proprietary Ig and Ig -expressing myeloma.
(NOTE: Should the Client provide pre-immunized mice, Abeome will adjust program fees accordingly.)
Clone selection and culturing
Hybridomas are screened using fluorescent activated cell sorting instrumentation, with reactive hybridomas deposited as single cells into 96-well culture plates.
Colonies arising from sorted cells are then screened by ELISA for reactivity with the Client's antigen. Positive colonies are screened for stability, isotyping by ELISA, and level of surface expression. Screening results are shared with the Client who may decide which clones (up to six clones for a three-mouse Program) they wish to pursue. Alternatively, the client may elect to take all positives.
Client-selected clones are grown in culture and frozen for delivery. Culture supernatants (up to 50 ml total) are also delivered to the Client (up to six).
The Client may send a scientific representative to inspect the sorting process.
Return to top
For additional information regarding Abeome's Standard Hybridoma Development Program, please contact info@abeomecorp.com
Abeome commercialization strategy involves licensing the
platform technology and also demonstrating the power of the
technology by developing biomarker libraries for interested
companies. We encourage prospective licensees to engage in a
prototype project to “test drive” the technology by engaging in
at least one 3-mouse study using an antigen of interest. This
provides the prospective licensee with the opportunity to see
the technology work first-hand.